Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mixed evidence
5 of 11 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
15 of 23 studies with measurable effects showed benefit.
Top outcomes
250-500mg daily (varies by form)
Morning or with meals, Alpha-GPC before cognitive tasks
Alpha-GPC or CDP-Choline (Citicoline)
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
2-4 weeks
4-8 weeks
1-2 weeks
With high doses
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Association of choline and betaine with the risk of cardiovascular disease and all-cause mortality: Meta-analysis
European journal of clinical investigation (2023) · Meta analysis · n=33009
Random-effects model results showed that highest versus lowest quantile of circulating choline concentrations were associated with the risk of CVD (RR = 1.29, 95% CI: 1.04-1.61) and all-cause mortality (RR = 1.62, 95% CI: 1.12-2.36).
Higher dietary choline intake is associated with increased risk of all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of cohort studies
Nutrition research (New York, N.Y.) (2024) · Meta analysis · n=482778
This study showed that each 100 mg/day increment in choline consumption was significantly associated with a 6% and 11% higher risk of all-cause and cardiovascular disease mortality respectively.
Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis
Journal of Alzheimer's disease : JAD (2023) · Meta analysis · n=1326
We found significant effects of α-GPC in combination with donepezil on cognition [4 RCTs, mean difference (MD):1.72, 95% confidence interval (CI): 0.20 to 3.25], functional outcomes [3 RCTs, MD:0.79, 95% CI: 0.34 to 1.23], and behavioral outcomes [4 RCTs; MD: -7.61, 95% CI: -10.31 to -4.91].
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
Nature communications (2025) · Meta analysis · n=5205
Mean body mass index (BMI) was 27.5 kg/m2 (SD = 5.3), with 51% female and 17% Black race/ethnicity.
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Based on meta-analysis of α-GPC with donepezil showing cognitive benefits and citicoline studies. Effects vary significantly by choline form - α-GPC and CDP-choline show higher bioavailability. Most evidence is in older adults or those with existing cognitive impairment.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 9/10) and wins in 1 of 3 categories.
For reduce inflammation, Omega-3 has a higher relevance score (90 vs 85).
No known interactions between Choline and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.